Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.19.08 | Pituitary–Acromegaly | ECE2015

Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

Auriemma Renata S , Grasso Ludovica F S , Galdiero Mariano , Pivonello Claudia , Salzano Ciro , Negri Mariarosaria , Angelis Cristina de , Colao Annamaria , Pivonello Rosario

Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromega...

ea0037ep48 | Adrenal cortex | ECE2015

The treatment with ‘dual release' hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC

Simeoli Chiara , De Martino Maria Cristina , Iacuaniello Davide , Mannarino Teresa , Cozzolino Alessia , De Leo Monica , Pivonello Claudia , Negri Mariarosaria , De Angelis Cristina , Colao Annamaria , Pivonello Rosario

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, life-long glucocorticoid (GC) treatment is often required to replace cortisol deficiency and to avoid the ACTH-dependent androgen levels increase. However, in these patients, the multiple daily doses required with conventional GCs can cause cortisol overexposure, leading to an increased risk of metabolic syndrome (MS), an impaired quality of life (QoL), and poor treatment compliance (TC). T...

ea0035oc7.3 | IGF-1 and Thyroid Basic | ECE2014

Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental models of hepatocellular carcinoma (HCC)

Pivonello Claudia , Negri Mariarosaria , De Martino Maria Cristina , de Angelis Cristina , Napolitano Maria , Izzo Francesco , Colao Annamaria , Hofland Leo J. , Pivonello Rosario

The mTOR and IGF/insulin pathways are frequently dysregulated in HCC. Antitumoral activity of mTOR inhibitors (mTORi) has been demonstrated in experimental models but in early clinical studies mTORi alone have shown modest antitumoral activity. IGF/insulin-dependent Akt activation, via IGF1R and IR, has been suggested as potential mechanism for mTORi resistance. This study aimed at evaluating the expression of mTOR and IGF/insulin pathway components and the effects of mTORi al...

ea0029p1379 | Pituitary Clinical | ICEECE2012

Epidemiology, histophatological characteristics and clinical manifestations of aggressive pituitary tumors, evaluated on the basis of KI-67 immunostaining: a single center experiense

Grasso L. , De Angelis M. , Di Somma C. , Savanelli C. , Galdiero M. , Cozzolino A. , Cavallo L. , Cappabianca P. , Del Basso De Caro M. , Pivonello R. , Colao A.

Aggressive pituitary tumors are classically defined as pituitary tumors with large size, rapid growth and massive invasion of surrounding anatomical structures. This is a group of pituitary tumors with biological behavior between pituitary adenomas and carcinomas and includes a new group of pituitary tumor, defined atypical adenoma, characterized by the presence of invasive growth and combination of increased mitotic activity and a Ki-67 labeling index >3%. The aim of this...

ea0026p74 | Endocrine tumours and neoplasia | ECE2011

In vitro effect of the somatostatin analogue BIM 23704 on cell cycle timecourse in an ovarian carcinoma cell line

de Angelis Cristina , Pivonello Claudia , Cuomo Gaia , Sardo Attilio di Spiezio , Bifulco Guiseppe , Nappi Carmine , Sabbatino Francesco , Cariati Federica , Colao Annamaria , Pivonello Rosario

Ovarian carcinoma (OC) is associated with poor prognosis and low survival rate. Eligible treatment for advanced OC is surgery followed by chemotherapy based on a combination of Platinum and Taxol, but unfortunately long-term outcome of such therapy is disappointing. Moreover, systemic administration of cytotoxic agents is usually accompanied by a series of side effects. On the basis of this evidence, more selective and tumour cell-targeted therapeutic approaches are warranted....

ea0056p387 | Diabetes (to include epidemiology, pathophysiology) | ECE2018

The effect of the dopamine agonist cabergoline on insulin sensitivity in the skeletal muscle: an in vitro study in a mouse cell model demonstrating mediation by serotoninergic receptors

Negri Mariarosaria , Pivonello Claudia , Gennaro Gilda Di , Angelis Cristina de , Simeoli Chiara , Iacuaniello Davide , Nettore Immacolata Cristina , Macchia Paolo Emidio , Muscogiuri Giovanna , Colao Annamaria , Pivonello Rosario

Insulin resistance (IR), characterized by an impairment of target tissues to insulin responsiveness, is the core defect preceding diabetes. Preclinical and clinical data have suggested a role for the dopaminergic system in glucose homeostasis control. The aim of the current study was to investigate the role of the dopamine agonist cabergoline (CAB), displaying high affinity for dopamine type 2 (DR2) receptor and low affinity for serotonin receptors (5-HTRs), in the regulation ...

ea0056p1008 | Endocrine Disruptors | ECE2018

A validated LC-Q-TOF-MS method for quantitative analysis of thyroxine and metabolites in placenta

Li Zhong-Min , Giesert Florian , Vogt-Weisenhorn Daniela , Main Katharina , Skakkebaek Niels , Kiviranta Hannu , Toppari Jorma , Feldt-Rasmussen Ulla , Shen Heqing , Schramm Karl-Werner , Angelis Meri De

Thyroid hormones (TH) of maternal origin are critical for the proper fetal development, especially during early pregnancy. Even minor changes in maternal TH circulation can lead to various adverse outcomes. Recent studies found that the metabolites of thyroxine (T4) also play an important physiological role. For example, 3,5-diiodo-L-thyronine (T2) and 3,3′-diiodo-L-thyronine (rT2) can suppress the thyroid stimulating hormone (TSH) level ...

ea0073pep13.1 | Presented ePosters 13: Pituitary and Neuroendocrinology | ECE2021

Factors associated with Aryl hydrocarbon Interacting Protein (AIP) expression in gonadotroph pituitary neuroendocrine tumours (Pit-NETs)

Polidoro Michela A. , Feola Tiziana , Gianno Francesca , Palumbo Valeria , Arcella Antonietta , Morace Roberta , De Angelis Michelangelo , Giangaspero Felice , Esposito Vincenzo , Jaffrain-Rea Marie-Lise

IntroductionAIP is a predisposing gene for GH/PRL-secreting PitNETs. Clinically non-functioning PitNETs (NFPT) occasionally occur in the setting of AIP germline mutations, sometimes arising from Pit-1 lineages. However, AIP overexpression has been observed in unselected NFPT and associations with the gonadotroph phenotype and/or tumour aggressiveness were suggested. We wished to evaluate the significance of AIP expression in gonadotroph tumours defined b...

ea0081p532 | Adrenal and Cardiovascular Endocrinology | ECE2022

Covid-19 in patients with hypocortisolism: clinical syndrome, disease duration and glucocorticoid replacement therapy

Simeoli Chiara , Schettino Serafina , La Rocca Angelica , Di Paola Nicola , Massimo Crescenzo Erminio , Ciardella Francesco , Mazzarella Alessandro , Pivonello Claudia , Colao Annamaria , Pivonello Rosario

Coronavirus disease caused by SARS-CoV-2 virus (Covid-19) is associated with a variable clinical syndrome, ranging from a mild-moderate to a severe disease, progressing towards acute respiratory distress syndrome. Hypocortisolism is associated with a depletion of innate immunity and disruption of immune response, which could contribute to an increased risk of infection and development of a severe disease. Glucocorticoid (GC) replacement therapy(GCRT), especially if administere...

ea0050oc5.6 | Reproduction and Neuroendocrinology | SFEBES2017

The MAPK effector B-Raf is essential for hypothalamic–pituitary axis development and activating mutations in BRAF cause congenital hypopituitarism

Kyprianou Nikolina , Gregory Louise , Lillina Vignola Maria , Besser Rachel , Marinelli Eugenia , Gualtieri Angelica , Scagliotti Valeria , Davis Shannon , Gevers Evelien , Dattani Mehul , Gaston-Massuet Carles

Somatic activating mutations in BRAF, encoding B-Raf, have been described in tumours and recently craniopharyngiomas. Germline mutations in BRAF and other components of the RAS/MAPK pathway are found in RASopathies, whose features include endocrine deficiencies but not craniopharyngiomas. We report three BRAF mutations (two of which are novel) in four children with congenital hypopituitarism. To demonstrate the functional role of the three variants w...